Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENvue Medical (FEED) Common Equity (2017 - 2025)

Historic Common Equity for ENvue Medical (FEED) over the last 12 years, with Q3 2025 value amounting to $42.5 million.

  • ENvue Medical's Common Equity rose 216837.61% to $42.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.5 million, marking a year-over-year increase of 216837.61%. This contributed to the annual value of $627000.0 for FY2024, which is 8427.78% down from last year.
  • As of Q3 2025, ENvue Medical's Common Equity stood at $42.5 million, which was up 216837.61% from $40.5 million recorded in Q2 2025.
  • In the past 5 years, ENvue Medical's Common Equity ranged from a high of $42.5 million in Q3 2025 and a low of $627000.0 during Q4 2024
  • For the 5-year period, ENvue Medical's Common Equity averaged around $9.4 million, with its median value being $4.1 million (2022).
  • Per our database at Business Quant, ENvue Medical's Common Equity crashed by 8427.78% in 2024 and then surged by 216837.61% in 2025.
  • ENvue Medical's Common Equity (Quarter) stood at $6.3 million in 2021, then crashed by 48.79% to $3.2 million in 2022, then increased by 23.35% to $4.0 million in 2023, then plummeted by 84.28% to $627000.0 in 2024, then surged by 6672.57% to $42.5 million in 2025.
  • Its Common Equity stands at $42.5 million for Q3 2025, versus $40.5 million for Q2 2025 and $35.7 million for Q1 2025.